UK Pharma Industry Bracing for Possible Disruption

From FierceBiotech: GlaxoSmithKline CEO Andrew Witty fears that if the European Medicines Agency (EMA) is moved from London, it will cause a tremendous disruption for the UK’s pharma and biotech industry. Experts worry about the possibility of regulatory upheaval if Brexit happens. The fate of the EMA is in the air. Brexit is currently in[…]

How Will UK Drug Regulation Be Affected by Brexit?

Now that the UK has voted to leave the European Union (EU), there are many questions being asked, Tracy Staton of FirePharma pointed out. The UK had been home to the EU’s European Medicines Agency (EMA) for most of their participation in the union, but that is no more with Brexit. The UK’s life sciences[…]